RU1777829C - Method for determination of conditions requiring korinfar - Google Patents
Method for determination of conditions requiring korinfarInfo
- Publication number
- RU1777829C RU1777829C SU904838916A SU4838916A RU1777829C RU 1777829 C RU1777829 C RU 1777829C SU 904838916 A SU904838916 A SU 904838916A SU 4838916 A SU4838916 A SU 4838916A RU 1777829 C RU1777829 C RU 1777829C
- Authority
- RU
- Russia
- Prior art keywords
- corinfar
- increase
- growth
- blood pressure
- taking
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относитс к медицине, а именно к кардиологии. Цель - повышение точности показаний. Способ реализуетс следующим образом: определ ют пророст артериального давлени и общего периферического сосудистого сопротивлени выполнени дозированной статической нагрузки до и после введени коринфара и при снижении прироста этих показателей после приема препарата по сравнению с исходными значени ми коринфар считают показанным. Использование предлагаемого способа обеспечивает высокую точность при определении показаний дл назначени коринфара при гипертонической болезни.The invention relates to medicine, namely cardiology. The goal is to increase the accuracy of readings. The method is implemented as follows: determine the growth of blood pressure and total peripheral vascular resistance of a dosed static load before and after the introduction of corinfar and with a decrease in the growth of these indicators after taking the drug compared to the initial values of corinfar considered considered. Using the proposed method provides high accuracy in determining the indications for the appointment of Corinfar in hypertension.
Description
Изобретение относитс к медицине, а именно кардиологии.The invention relates to medicine, namely cardiology.
Цель изобретени - повышение точности способа.The purpose of the invention is to improve the accuracy of the method.
Способ реализуетс следующим образом .The method is implemented as follows.
У больного гипертонической болезнью измер ют артериальное давление (АД) и показатели центральной гемодинамики с помощью метода терапол рной грудной реографии на реографе РГ-2-02. Провод т статическую нагрузку (СН) путем сжати ручного динамометра с усилием 50% от максимального дл данного больного в течение 60с с регистрацией АД и реограммы через 50 с нагрузки. Определ ют приросты диасто- лического АД и ОПСС на нагрузку. Больной принимает внутрь 10 мг коринфара и через 1.5 ч регистрирует АД и реограмму в покое и через 50 с повторной СН. Определ ют приросты ДАД и ОПСС на нагрузку. Сравнивают приросты ДАД и ОПСС до и послеIn a patient with hypertension, blood pressure (BP) and central hemodynamics are measured using the method of therapeutic chest rheography on a RG-2-02 rheograph. A static load (HF) is carried out by compressing a manual dynamometer with a force of 50% of the maximum for a given patient for 60 s with registration of blood pressure and rheogram after 50 s of load. The increments of diastolic blood pressure and OPSS per load are determined. The patient takes 10 mg of Corinfarum orally and after 1.5 hours registers blood pressure and rheogram at rest and after 50 seconds of repeated heart failure. The increments in DBP and OPSS per load are determined. The increments of DBP and OPSS are compared before and after
приема препарата. Если есть тенденци к повышению приростов ДАД и ОПСС, то длительное лечение препаратом не будет эф- фективным. При наличии тенденции к снижению приростов ДАД и ОПСС - длительна монотерапи коринфаром показана , при наличии снижени прироста ДАД и повышение ОПСС - гипотензивный эффект препарата не будет стабильным длительно.taking the drug. If there is a tendency to increase the growth of DBP and OPSS, then long-term treatment with the drug will not be effective. If there is a tendency to a decrease in the growth of DBP and OPSS, long-term monotherapy with Corinfarum is indicated; if there is a decrease in the increase in DBP and an increase in OPSS, the hypotensive effect of the drug will not be stable for a long time.
Пример. Больной Ш, 36 лет. диагноз: ГБ И ст. стаб. течени . Исходный уровень АД 180/110 мм рт.ст. Остра подъ зычна проба положительна : снижение АД до 140/90 мм рт.ст.Example. Patient W., 36 years old. diagnosis: GB And Art. stub currents. The initial level of blood pressure 180/110 mm RT.article The acute sublingual test is positive: a decrease in blood pressure to 140/90 mm Hg.
Остра пероральна проба с применением СП положительна : прирост ДАД при СН до приема 10 мг коринфара составил 27%, прирост ОПСС - 26%, после приема препарата прирост ДАД на СН составил 22%, прирост ОПСС-17%. В течение года гипотензивный эффект коринфара (суточна The acute oral test with the use of SP is positive: the increase in DBP for HF before taking 10 mg of Corinfar was 27%, the increase in OPSS was 26%, after taking the drug, the increase in DBP for CH was 22%, the increase in OPSS was 17%. During the year, the hypotensive effect of Corinfar (daily
//
WW
ёё
vl vjvl vj
VJ 00Vj 00
ГОGO
чэche
доза 60 мг) полный и стабильный: АД со-парата и регистрации показателей центставл ет 140/95 мм рт.ст.ральной гемодинамики, отличающийс dose 60 mg) complete and stable: blood pressure and registration of blood counts are 140/95 mm Hg of oral hemodynamics, different
Предлагаемый способ обеспечивает вы-тем. что. с целью повышени точности, досокую точность при определении показанийполнительно определ ют прирост артериальдл назначени коринфара при гипертони-5 ного давлени и общего периферическогоThe proposed method provides you. what. in order to increase accuracy, the accuracy of the arterial coronary arterial coronary arteries with hypertension-5 pressure and total peripheral
ческой болезни. сосудистого сопротивлени на фоне проведени дозированной статической нагрузки до иdisease. vascular resistance against the background of a dosed static load to and
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU904838916A RU1777829C (en) | 1990-06-12 | 1990-06-12 | Method for determination of conditions requiring korinfar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU904838916A RU1777829C (en) | 1990-06-12 | 1990-06-12 | Method for determination of conditions requiring korinfar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU1777829C true RU1777829C (en) | 1992-11-30 |
Family
ID=21520744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU904838916A RU1777829C (en) | 1990-06-12 | 1990-06-12 | Method for determination of conditions requiring korinfar |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU1777829C (en) |
-
1990
- 1990-06-12 RU SU904838916A patent/RU1777829C/en active
Non-Patent Citations (1)
| Title |
|---|
| Opicl. Z.H. Jennings A.A Role og calcium channel. Amer. I. Meg. 1986. N 6A, p. 35-72. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LEWIS et al. | The dynamics of both right and left ventricles at rest and during exercise in patients with heart failure | |
| Shinebourne et al. | Effects of beta-adrenergic blockade during exercise in hypertensive and ischaemic heart-disease | |
| Delea | Chronobiology of blood pressure | |
| Nakamura et al. | Attenuated endothelium-dependent peripheral vasodilation and clinical characteristics in patients with chronic heart failure | |
| Baily et al. | Direct neurohumoral evidence for isolated sympathetic nervous system activation to skeletal muscle in response to cardiopulmonary baroreceptor unloading. | |
| Cowley et al. | Captopril therapy for heart failure: a placebo controlled study | |
| LILLINGTON et al. | The cardiorespiratory syndrome of obesity | |
| Jones et al. | Absence of age-related decline in total blood volume in physically active females | |
| Levenson et al. | Post-synaptic alpha-blockade and brachial artery compliance in essential hypertension | |
| Pietras et al. | Cardiovascular response in hyperthyroidism: The influence of adrenergic-receptor blockade | |
| Dintenfass et al. | Exercise fitness, cardiac work and blood viscosity factors in patients and normals | |
| Stojceva-Taneva et al. | Autonomic nervous system dysfunction and volume nonresponsive hypotension in hemodialysis patients | |
| Verhaegen et al. | The arteriolar effects of cinnarizine and flunarizine: multitechnical investigations in normal volunteers and in patients with occlusive disease of the extremities secondary to arteriosclerosis | |
| Sinoway | Effect of conditioning and deconditioning stimuli on metabolically determined blood flow in humans and implications for congestive heart failure | |
| RU1777829C (en) | Method for determination of conditions requiring korinfar | |
| Gould et al. | Cardiac effects of two cocktails in normal man | |
| Rodríguez-Pérez et al. | Platelet cytosolic calcium, peripheral hemodynamics, and vasodilatory peptides in liver cirrhosis | |
| Cotton et al. | Symmetric peripheral gangrene complicating acute myocardial infarction | |
| Abelmann et al. | The circulation of the blood in alcohol addicts; the cardiac output at rest and during moderate exercise | |
| SIGLER et al. | The diagnosis of cardiac aneurysm with report of two cases | |
| Gould et al. | Effects of Alcohol on the Systolic Time lntervals | |
| Gould et al. | Cardiac effects of alcohol in alcoholics | |
| Reid et al. | Guanfacine: effects of long-term treatment and withdrawal | |
| Safar et al. | Antihypertensive therapy with uncontrolled systolic pressure and increased aortic rigidity | |
| Coplan et al. | Comparison of arm and treadmill exercise at 85% predicted maximum heart rate |